A Study Of Clonal Hematopoiesis And Epigenetic Biomarkers Of Biological Aging In Patients With AHCT

Overview

About this study

The purpose of this study is to quantify the burden of biological aging and CH in patients with autoimmune diseases undergoing AHCT. Assess the impact of AHCT on biological aging and CH in patients with autoimmune diseases.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients with autoimmune diseases who are undergoing autologous stem cell transplant as standard of care will be eligible to participate in the study.

Exclusion Criteria:

  • Patients who do not have autoimmune diseases, or are not undergoing autologous stem cell transplant as standard of care.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 8/1/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Madiha Iqbal

Open for enrollment

Contact information:

Clinical Studies Unit

(904) 953-2255

More information

Publications

Publications are currently not available
.
CLS-20597197

Mayo Clinic Footer